MeiraGTx Holdings (MGTX) Research & Development (2017 - 2025)
MeiraGTx Holdings' (MGTX) quarterly Research & Development came in at $476000.0 in Q4 2025, up 100.66% YoY from $237212.7 in Q4 2024, and up 52.08% on a QoQ basis from $313000.0 in Q3 2025.
MeiraGTx Holdings (MGTX) Research & Development (2017 - 2025) Analysis & Trends
MeiraGTx Holdings (MGTX) has 9 years of Research & Development data on file, last reported at $476000.0 in Q4 2025.
- Quarterly Research & Development rose 100.66% year-over-year to $476000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.8 million (down 79.64% YoY) and the FY2025 annual result came in at $4.8 million, down 79.64% from the prior year.
- Research & Development improved to $476000.0 in Q4 2025, from $313000.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $34.9 million in Q2 2024 to a low of -$71.7 million in Q4 2024.
- A 5-year average of $14.2 million and a median of $20.8 million in 2021 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2021 — Research & Development surged 367.21% — and 2024, when it plunged 312.97%.
- Tracing MGTX's Research & Development over 5 years: stood at $13.2 million in 2021, then jumped by 65.11% to $21.8 million in 2022, then jumped by 54.7% to $33.7 million in 2023, then sank by 312.97% to -$71.7 million in 2024, then surged by 100.66% to $476000.0 in 2025.
- The last three Research & Development figures came in at $476000.0 (Q4 2025), $313000.0 (Q3 2025), and $2.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | MeiraGTx Holdings | 1.10 Bn | 1.03 Bn | - | 476,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 476,000.00 |
| Sep 30, 2025 | 313,000.00 |
| Jun 30, 2025 | 2.68 Mn |
| Mar 31, 2025 | 1.38 Mn |
| Dec 31, 2024 | -71.71 Mn |
| Sep 30, 2024 | 26.24 Mn |
| Jun 30, 2024 | 34.93 Mn |
| Mar 31, 2024 | 34.32 Mn |
| Dec 31, 2023 | 33.67 Mn |
| Sep 30, 2023 | 27.86 Mn |
| Jun 30, 2023 | 19.94 Mn |
| Mar 31, 2023 | 22.32 Mn |
| Dec 31, 2022 | 21.77 Mn |
| Sep 30, 2022 | 16.86 Mn |
| Jun 30, 2022 | 24.00 Mn |
| Mar 31, 2022 | 23.10 Mn |
| Dec 31, 2021 | 13.18 Mn |
| Sep 30, 2021 | 21.61 Mn |
| Jun 30, 2021 | 15.19 Mn |
| Mar 31, 2021 | 16.71 Mn |